Literature DB >> 30655610

Getting closer to a cure for migraine.

Cristina Tassorelli1,2, Roberto De Icco3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30655610     DOI： 10.1038/s41582-019-0134-z

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.

Authors:  Rashmi B Halker Singh; Ernesto Aycardi; Marcelo E Bigal; Pippa S Loupe; Mirna McDonald; David W Dodick
Journal:  Cephalalgia       Date:  2018-05-03       Impact factor: 6.292
  1 in total
  3 in total

1.  Human Urinary Kallidinogenase Reduces Lipopolysaccharide-Induced Neuroinflammation and Oxidative Stress in BV-2 Cells.

Authors:  Zhongyan Zhao; Zhiyu Xu; Tao Liu; Shixiong Huang; Huai Huang; Xiaoyun Huang
Journal:  Pain Res Manag       Date:  2019-07-24       Impact factor: 3.037

2.  Curcumin Protects Human Umbilical Vein Endothelial Cells against H2O2-Induced Cell Injury.

Authors:  Jipeng Ouyang; Rong Li; Haiqin Shi; Jianping Zhong
Journal:  Pain Res Manag       Date:  2019-09-02       Impact factor: 3.037

3.  Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials.

Authors:  I-Hsin Huang; Po-Chien Wu; Ya-Han Lee; Yi-No Kang
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.